MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from exercise of
stock options
$294K
Net cash provided by
financing activities
$294K
Net (decrease)
increase in cash, cash...
-$70,361K
Canceled cashflow
$294K
Stock-based compensation
expense
$15,582K
Accounts receivable, net
-$6,303K
Loss on disposal of
items of property and...
-$4,866K
Accounts payable
$3,719K
Operating lease
liabilities
$1,768K
Non-cash interest
expense
$1,381K
Depreciation and
amortization expense
$1,283K
Net cash used in
operating activities
-$65,993K
Net cash used in
investing activities
-$4,662K
Canceled cashflow
$34,902K
Revenue
$10,785K
Interest income
$6,050K
Other non-operating
items
$1,455K
Net loss
-$88,612K
Purchases of property and
equipment
$4,662K
Canceled cashflow
$18,290K
Accrued expenses
-$8,441K
Operating lease assets
$1,857K
Change in fair value of
derivative liabilities
$1,455K
Prepaid expenses and
other current assets
$357K
Inventory
$173K
Axpaxli
$42,460K
Stock-based compensation
$15,582K
Selling & marketing
$14,075K
Unallocated expenses,
personnel costs
$12,976K
General &
administrative
$11,606K
Interest expense
$2,777K
Facilities
$2,270K
Unallocated expenses, all
other costs
$1,809K
Cost of product
revenue
$1,329K
Depreciation
$1,260K
Direct program
expenses, other clinical...
$758K
Back
Back
Cash Flow
source: myfinsight.com
OCULAR THERAPEUTIX, INC (OCUL)
OCULAR THERAPEUTIX, INC (OCUL)